

Stockhead V-Con: Medicinal Cannabis Presentation

Neurotech International Limited (ASX: NTI) ("Neurotech" "NTI" or "the Company") is pleased to announce that our company chairman, Mr Brian Leedman has made a presentation at Stockhead's virtual conference on Medicinal Cannabis – The Future of Pharma.

*As medicinal cannabis is now legalised in over 30 countries, the opportunities for future growth, domestically and internationally, are significant. The global market is estimated to be worth A\$80 billion by 2024. Locally, the Australian medicinal cannabis market saw strong growth throughout 2021, with medical cannabis prescriptions at an all-time high, and revenue from product sales reaching A\$230 million.

The number of medicinal cannabis users has escalated over the past five years in Australia. Last year alone more than 86,000 applications were lodged, with the number forecast to surpass 100,000 in 2022. Demand for the product is set to climb even further by 2030, with approximately 670,000 patients predicted to be seeking access to medicinal cannabis in Australia, requiring approximately 79,000 kg of dried plant matter. In this V-con, the highs of this booming industry and what we can expect from ASX listed companies in this space will be explored.

Please click on the link to the virtual conference from midday EST today:
<https://stockhead.com.au/stockhead-tv/v-cons/>

**Source: Stockhead*

Authority

This announcement has been authorised for release by the Chairman of Neurotech International Limited.

Further Information

Dr Alexandra Andrews

CEO

aa@neurotechinternational.com

+61 (0)405 339 788

Brian Leedman

Chairman

b.leedman@neurotechinternational.com

+61 (0)41 228 1780

Media:

Jane Lowe

IR Department

jane.lowe@irdepartment.com.au

+61 (0)411 117 774

About Neurotech

Neurotech International Limited is a medical device and solutions company conducting clinical studies to assess the neuro-protective, anti-inflammatory and neuro-modulatory activities of our proprietary NTI/Dolce cannabis strains. Neurotech is also commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity. For more information about Neurotech and Mente Autism please visit <http://www.neurotechinternational.com>